Physician profile
Dasom Chun
NPI 1316627714
$1,311.48
in general payments reported to CMS, 2019-2025
15 companies · $603 in 2025
The $603 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $70.10 · 2024: $638 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207.52 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $185.53 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Vivus LLC | $147.00 | 2024-2025 | Pancreaze |
| Kowa Pharmaceuticals America, INC. | $105.68 | 2024-2025 | Zoryve |
| Abbvie INC. | $102.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.76 | 2025 | Airsupra, Farxiga, Breztri |
| Shield Therapeutics INC | $92.55 | 2024-2025 | |
| Dexcom, INC. | $80.49 | 2024 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $78.65 | 2023-2024 | Ztlido |
| Aimmune Therapeutics, INC. | $45.99 | 2025 | Zenpep |
| Ardelyx, INC. | $40.64 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $39.79 | 2025 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $34.25 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.50 | 2025 | Jardiance |
| Exact Sciences Corporation | $20.73 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dasom Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.